Compras y ventas de directivos de Edwards Lifesciences (EW)
Qué compran y venden los consejeros y directivos del S&P 500 en sus propias empresas, tal cual lo presentan en los Formularios 4 de la SEC (2 días hábiles de plazo): cada fila con su código oficial y sin filtrar nada.
Las compras en mercado abierto (código P) son la señal rara, en verde; las ventas (código S) son frecuentes y muchas van programadas (10b5-1). La tabla II (derivados) no se incluye: sus precios son de ejercicio, no de mercado. Guía: compras de directivos.
| Fecha | Ticker | Directivo | Cargo | Acciones | Precio | Importe | % posición | Tipo / documento |
|---|
Descargar estas transacciones en CSV Sin cuenta y sin registro. Los datos son públicos: salen de los Formularios 4 de la SEC.
Compras y ventas de directivos de Edwards Lifesciences Corporation (EW): ninguna compra y 44 ventas
147 transacciones de la tabla I del Formulario 4 declaradas ante la SEC por directivos de Edwards Lifesciences Corporation entre el 2025-08-25 y el 2026-10-08 (histórico de 15 meses): 0 compras y 44 ventas en mercado abierto, y 103 transacciones con otros códigos del Formulario 4, desglosados uno a uno más abajo. La mayor operación en mercado abierto es una venta de $2,9M de Chopra Daveen el 2026-08-26.
Compras y ventas de directivos de Edwards Lifesciences en los últimos 12 meses
Entre el 21 oct 2025 y el 20 oct 2026, los directivos de Edwards Lifesciences declararon 43 ventas por $27,7M en mercado abierto, y ninguna compra.
Quien más vendió fue Bobo Donald E Jr (CVP, Strategy/Corp Development): $11,2M en 8 ventas, de 9 vendedores distintos.
La mayor operación del período fue una venta de $2,9M el 26 ago 2026, de Chopra Daveen (CVP, TMTT, Surgical & IHFM). Formulario 4 en sec.gov (0001225208-26-007335).
De las 43 ventas, 25 (el 58%, $14,5M) llevan en el Formulario 4 la marca de plan 10b5-1, es decir, se programaron con meses de antelación; las otras 18 no la llevan.
En los tres últimos meses hay 10 ventas, frente a 12 en los tres anteriores. La última venta es del 8 oct 2026.
Frente a su sector (Salud, 59 empresas con página de directivos en esta web), en las mismas fechas la mediana es de 9 ventas y 0 compras en mercado abierto. Edwards Lifesciences tiene más ventas que 55 de las otras 58, es la 25.ª de 59 por dinero neto vendido, y 19 de las 59 tienen al menos una compra.
Las 20 operaciones más importantes
Como EW no tiene compras en mercado abierto, la tabla empieza por sus ventas, de mayor a menor importe. El histórico completo está en la herramienta de arriba, ya buscado.
Ver las 147 operaciones de EW en el histórico completo →
| Operación | Declarada | Directivo | Cargo | Importe | Código | Documento |
|---|---|---|---|---|---|---|
| 2026-08-26 | 2026-08-26 | Chopra Daveen | CVP, TMTT, Surgical & IHFM | $2,9M | S — Venta en mercado abierto2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 This transaction was executed in multiple trades at prices ranging from $91.660 to $91.975. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 This transaction was executed in multiple trades at prices ranging from $90.645 to $91.640. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-05-12 | 2026-05-12 | Zovighian Bernard J | CEO | $2,8M | S — Venta en mercado abierto (programada 10b5-1) Tenencia indirecta, a través de: By Trust 3 notas del Formulario 4 (texto original de la SEC, en inglés)F2 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F3 This transaction was executed in multiple trades at prices ranging from $78.390 to $78.430. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F4 This transaction was executed in multiple trades at prices ranging from $77.375 to $78.360. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-02-25 | 2026-02-26 | Bobo Donald E Jr | CVP, Strategy/Corp Development | $2,0M | S — Venta en mercado abierto2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 This transaction was executed in multiple trades at prices ranging from $83.66 to $83.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 Total reflects the correction of 13,396 shares held indirectly by the Reporting Person's trust, which were previously reported as directly held. | SEC |
| 2026-05-27 | 2026-05-27 | Bobo Donald E Jr | CVP, Strategy/Corp Development | $2,0M | S — Venta en mercado abierto Tenencia indirecta, a través de: By Trust Nota del Formulario 4 (texto original de la SEC, en inglés)F1 This transaction was executed in multiple trades at prices ranging from $86.27 to $86.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2025-12-08 | 2025-12-10 | Zovighian Bernard J | CEO | $1,8M | S — Venta en mercado abierto (programada 10b5-1)2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. F2 This transaction was executed in multiple trades at prices ranging from $84.63 to $85.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-04-02 | 2026-04-02 | Bobo Donald E Jr | CVP, Strategy/Corp Development | $1,8M | S — Venta en mercado abierto (programada 10b5-1)3 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. F2 This transaction was executed in multiple trades at prices ranging from $80.510 to $80.660. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $79.490 to $80.435. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-02-12 | 2026-02-13 | Zovighian Bernard J | CEO | $1,7M | S — Venta en mercado abierto2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 This transaction was executed in multiple trades at prices ranging from $77.080 to $77.225 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 This transaction was executed in multiple trades at prices ranging from $76.080 to $77.075 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-05-15 | 2026-05-18 | Bobo Donald E Jr | CVP, Strategy/Corp Development | $1,5M | S — Venta en mercado abierto Tenencia indirecta, a través de: 401(k) Nota del Formulario 4 (texto original de la SEC, en inglés)F1 This transaction was executed in multiple trades at prices ranging from $81.975 to $82.260. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-03-11 | 2026-03-11 | Ullem Scott B. | CVP, Chief Financial Officer | $1,1M | S — Venta en mercado abierto (programada 10b5-1)3 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025. F2 This transaction was executed in multiple trades at prices ranging from $83.865 to $84.860. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $84.865 to $85.790. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2025-11-10 | 2025-11-10 | Ullem Scott B. | CVP, Chief Financial Officer | $1,1M | S — Venta en mercado abierto (programada 10b5-1)3 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025. F2 This transaction was executed in multiple trades at prices ranging from $83.270 to $83.415. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $82.270 to $83.260. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-04-09 | 2026-04-09 | Ullem Scott B. | CVP, Chief Financial Officer | $1,0M | S — Venta en mercado abierto (programada 10b5-1)3 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025. F2 This transaction was executed in multiple trades at prices ranging from $80.225 to $80.750. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $79.210 to $80.200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-03-02 | 2026-03-02 | Bobo Donald E Jr | CVP, Strategy/Corp Development | $974k | S — Venta en mercado abierto (programada 10b5-1)2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. F2 This transaction was executed in multiple trades at prices ranging from $85.665 to $86.380. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-01-06 | 2026-01-06 | Bobo Donald E Jr | CVP, Strategy/Corp Development | $971k | S — Venta en mercado abierto (programada 10b5-1)3 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. F2 This transaction was executed in multiple trades at prices ranging from $84.39 to $85.25. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $85.40 to $86.10. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2025-12-12 | 2025-12-12 | Bobo Donald E Jr | CVP, Strategy/Corp Development | $954k | S — Venta en mercado abierto | SEC |
| 2025-12-10 | 2025-12-10 | Bobo Donald E Jr | CVP, Strategy/Corp Development | $951k | S — Venta en mercado abierto (programada 10b5-1)2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. F2 This transaction was executed in multiple trades at prices ranging from $83.465 to $84.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-07-28 | 2026-07-28 | Markowitz Wayne | CVP, JAPAC | $819k | S — Venta en mercado abierto | SEC |
| 2025-12-09 | 2025-12-09 | Ullem Scott B. | CVP, Chief Financial Officer | $650k | S — Venta en mercado abierto (programada 10b5-1)2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025. F2 This transaction was executed in multiple trades at prices ranging from $84.09 to $85.07. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2025-12-10 | 2025-12-10 | Zovighian Bernard J | CEO | $322k | S — Venta en mercado abierto (programada 10b5-1) Tenencia indirecta, a través de: By Trust Nota del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. | SEC |
| 2026-07-27 | 2026-07-27 | Zovighian Bernard J | CEO | $245k | S — Venta en mercado abierto Tenencia indirecta, a través de: By Trust | SEC |
| 2026-08-28 | 2026-08-28 | Bruls Annette | CVP, EMEACLA | $238k | S — Venta en mercado abierto | SEC |
El saldo del período: cuánto dinero entra y cuánto sale
En los Formularios 4 presentados entre el 25 ago 2025 y el 8 oct 2026 no consta ni una compra en mercado abierto de Edwards Lifesciences Corporation: 44 ventas por $27,9M y cero dólares comprados.
Solo cuentan los códigos P y S, donde el directivo pone o saca su propio dinero. Que el saldo de Edwards Lifesciences Corporation salga vendedor es lo habitual en el S&P 500, donde buena parte del sueldo se cobra en acciones. No es una recomendación de comprar ni de vender: es lo que se declaró.
Todas las transacciones, código por código
| Código | Qué significa | Operaciones | Importe declarado |
|---|---|---|---|
| S | Venta en mercado abierto | 44 | $27,9M |
| F | Retención fiscal (acciones entregadas por impuestos) | 38 | $7,1M |
| M | Ejercicio de opciones | 30 | $13,6M |
| A | Adjudicación o premio de acciones | 20 | $0 |
| G | Regalo o donación | 15 | $0 |
| Total | Todo lo declarado en el período | 147 | $48,7M |
39 de las 147 filas no traen un importe utilizable en el Formulario 4: cuentan como operación y suman $0. Las etiquetas son las del índice de códigos de la SEC.
Quién ha operado
En los 15 meses del histórico han declarado operaciones de Edwards Lifesciences Corporation 17 personas o entidades distintas. De ellas, ninguna compró en mercado abierto y 9 vendieron. Se cuentan por su CIK, el número fijo que la SEC da a cada declarante, y no por el nombre, que cada uno escribe a su manera.
De los 9 que vendieron en mercado abierto (44 ventas en total), los tres que más vendieron suman $22,0M de los $27,9M: el 79% del dinero en tres personas.
| Declarante | Cargo | Transacciones | Comprado (nº) | Vendido (nº) | Última declarada |
|---|---|---|---|---|---|
| Bobo Donald E Jr | CVP, Strategy/Corp Development | 19 | — | $11,2M (8) | 2026-05-27 |
| Zovighian Bernard J | CEO | 28 | — | $7,0M (6) | 2026-07-27 |
| Ullem Scott B. | CVP, Chief Financial Officer | 16 | — | $3,9M (4) | 2026-05-11 |
| Chopra Daveen | CVP, TMTT, Surgical & IHFM | 13 | — | $3,4M (4) | 2026-09-11 |
| Markowitz Wayne | CVP, JAPAC | 13 | — | $1,0M (5) | 2026-09-14 |
| Lippis Daniel J. | CVP, TAVR | 36 | — | $925k (13) | 2026-10-08 |
| Bruls Annette | CVP, EMEACLA | 4 | — | $238k (1) | 2026-08-28 |
| Stone Heisz Leslie | Consejero | 2 | — | $218k (1) | 2026-05-08 |
Se enseñan los 8 que más dinero movieron, de 17. Los demás están en el histórico completo, que se abre con el enlace de arriba. El nombre lleva a todas sus operaciones, en cualquier empresa. «Transacciones» cuenta cualquier código; el dinero, solo mercado abierto. Cargo: el de su última declaración.
Mes a mes
Por el mes en que se operó, no en el que se presentó el formulario; los meses sin operaciones van a cero. El mes con más movimiento fue dic 2025: 0 compras y 9 ventas, por $5,2M. 2 de los 15 meses no tienen ninguna.
| Mes | Compras | Importe | Ventas | Importe |
|---|---|---|---|---|
| ago 2025 | 0 | $0 | 1 | $205k |
| sept 2025 | 0 | $0 | 0 | $0 |
| oct 2025 | 0 | $0 | 0 | $0 |
| nov 2025 | 0 | $0 | 2 | $1,2M |
| dic 2025 | 0 | $0 | 9 | $5,2M |
| ene 2026 | 0 | $0 | 2 | $1,1M |
| feb 2026 | 0 | $0 | 2 | $3,7M |
| mar 2026 | 0 | $0 | 3 | $2,2M |
| abr 2026 | 0 | $0 | 3 | $2,9M |
| may 2026 | 0 | $0 | 9 | $6,7M |
| jun 2026 | 0 | $0 | 2 | $103k |
| jul 2026 | 0 | $0 | 4 | $1,1M |
| ago 2026 | 0 | $0 | 5 | $3,4M |
| sept 2026 | 0 | $0 | 1 | $54k |
| oct 2026 | 0 | $0 | 1 | $53k |
El último mes puede ir incompleto: el Formulario 4 se presenta hasta dos días hábiles después. La tabla no dice si el patrón es bueno o malo; dice cuándo pasó.
Ficha de análisis de Edwards Lifesciences Corporation (EW) →
Otras empresas de Salud con operaciones de directivos
Están las 500 en el índice de la sección →
Qué directivos están comprando acciones de su propia empresa →
Cómo leer estos datos
11 de las 20 ventas de la tabla van marcadas como programadas (plan 10b5-1): se firman con meses de antelación y se ejecutan solas, así que no dicen lo que el directivo piensa hoy. Edwards Lifesciences no tiene ninguna compra en mercado abierto (código P) en el histórico, que es lo más común en el S&P 500: los directivos ya cobran en acciones. La última presentación es del 8 oct 2026, y el Formulario 4 llega hasta dos días hábiles después de operar.
16 de las 20 filas de la tabla llevan notas al pie del propio Formulario 4, plegadas en la columna del código y copiadas tal cual, en inglés; una fila sin nota es que el formulario no la trae.
Guía: Compras de directivos · todas las guías
Lo que hay detrás de estas operaciones
Los conceptos de esta página, explicados desde cero en la Academia. Gratis y sin cuenta.
- Qué dice y qué NO dice la hipótesis de eficienciaSi la compra de un directivo es pública y cualquiera puede leerla, ¿queda información dentro? Es la pregunta exacta que trae a esta página.
- Quién mueve realmente el mercado: los tipos de inversoresQuién hay al otro lado de cada orden, y qué sitio ocupan entre ellos los directivos de la propia empresa.
- Oferta, demanda y el precio: por qué sube y baja constantementeCómo acaba una noticia metida en el precio, y por qué la reacción a una venta declarada rara vez es la que uno esperaría.
Fuente: SEC EDGAR Formulario 4. Esto es una lista de hechos públicos, no asesoramiento financiero ni una recomendación de compra o venta.